合約開發和生產組織 (CDMO) 市場分析及預測至 2035 年：類型、產品類型、服務、技術、應用、形式、最終用戶、流程和階段

預計到2034年，醫藥合約研發生產市場規模將從2024年的1,765億美元成長至3,357億美元，年複合成長率約為6.8%。醫藥合約研發生產市場涵蓋外部合作夥伴為製藥公司提供的服務，包括藥物研發、生產和包裝。該市場有助於提高成本效益和擴充性，使企業能夠專注於其核心競爭力。對學名藥、生物製藥和個人化醫療的需求不斷成長是推動市場成長的主要因素，而技術進步則提高了產能和合規性。

受藥物研發和生產外包需求不斷成長的推動，醫藥合約研發生產市場正經歷強勁成長。研發領域，尤其是製劑和製程研發，是推動市場成長的主要動力，這主要得益於對專業知識和先進技術的需求。生產服務，特別是生物製藥和生物相似藥的生產，緊隨其後，反映出市場對複雜生物製藥的日益關注。在這些領域中，小分子藥物研發子領域表現最為突出，受益於市場對學名藥的持續需求。同時，包括單株抗體和重組蛋白在內的大分子藥物生產子領域預計將呈現第二高的成長率，這主要得益於生物技術的進步。數位化技術和自動化在生產流程中的應用，有助於提高效率和品管。製藥公司與合約服務供應商之間的策略聯盟和合作，正在推動進一步的創新和市場擴張。

醫藥合約研發生產組織（CDMO）市場正經歷市場佔有率、定價和新產品上市方面的動態變化。主要企業正利用創新技術提升自身價值主張，進而形成充滿挑戰卻又機會無限的競爭格局。對成本效益高、生產效率高的流程的關注，推動了新產品的湧現。各公司正策略性地調整定價模式，以滿足醫藥產業不斷變化的需求，力求擴大市場佔有率。市場對專業服務的強勁需求是其成長和創新的主要驅動力。該行業的競爭標竿分析顯示，市場由少數幾家主要企業主導，而規模較小的企業則努力透過專業服務開闢利基市場。監管的影響至關重要，嚴格的合規要求塑造企業的策略。北美和歐洲對監管標準有著顯著的影響力，進而影響全球市場動態。亞太地區的新興市場由於有利的政策和基礎設施投資，正經歷日益活躍的市場環境。併購透過重塑市場邊界和刺激創新，進一步加劇了競爭。這項綜合分析強調了戰略靈活性和監管合規性在駕馭複雜的製藥行業中的重要性。

主要趨勢和促進因素：

受生物製藥和生物相似藥需求不斷成長的推動，醫藥合約研發生產市場正經歷強勁成長。這一趨勢源自於慢性病盛行率的上升以及對創新治療方案的需求。生物製藥公司正將研發和生產流程外包，以提高效率並專注於核心競爭力。另一個關鍵趨勢是個人化醫療的興起，這需要專業的生產能力。契約製造製造商正在投資先進技術，以支援小批量、高精度生產。對品質和法規遵從性的日益重視也是一個關鍵促進因素，促使企業與經驗豐富的契約製造合作，以應對複雜的監管環境。此外，醫藥供應鏈的全球化也為合約研發生產力機構（CDMO）在新興市場拓展業務創造了機會。隨著製藥公司尋求降低成本和提高柔軟性，與契約製造製造商建立策略合作夥伴關係變得日益重要。這些合作正在縮短新藥上市時間，從而推動市場成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制
• 複合年均成長率：成長分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 小分子藥物
  • 生物製藥
  • 先進療法藥物
• 市場規模及預測：依產品分類
  • 原料藥（API）
  • 最終劑型（FDF）
  • 中級
• 市場規模及預測：依服務分類
  • 配方開發
  • 製程開發
  • 分析服務
  • 臨床生產
  • 商業生產
  • 包裝
• 市場規模及預測：依技術分類
  • 冷凍乾燥
  • 噴霧乾燥
  • 奈米科技
  • 連續製造
• 市場規模及預測：依應用領域分類
  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 感染疾病
  • 免疫學
  • 呼吸系統
• 市場規模及預測：依類型
  • 固態的
  • 液體
  • 半固態
• 市場規模及預測：依最終用戶分類
  • 製藥公司
  • 生技公司
  • 研究所
• 市場規模及預測：依製程分類
  • 大量生產
  • 連續製造
• 市場規模及預測：依發展階段分類
  • 臨床前階段
  • 臨床
  • 商業的

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地區
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 亞太其他地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲地區

第6章 市場策略

• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章 公司簡介

• Catalent
• Lonza
• Recipharm
• Patheon
• Wu Xi App Tec
• Siegfried Holding
• Piramal Pharma Solutions
• Fujifilm Diosynth Biotechnologies
• Cambrex Corporation
• Almac Group
• Vetter Pharma
• Boehringer Ingelheim Bio Xcellence
• Ajinomoto Bio-Pharma Services
• Samsung Biologics
• Thermo Fisher Scientific
• Corden Pharma
• Fareva
• Hovione
• AMRI
• Baxter Bio Pharma Solutions

第9章：關於我們

Pharmaceutical Contract Development and Manufacturing Market is anticipated to expand from $176.5 billion in 2024 to $335.7 billion by 2034, growing at a CAGR of approximately 6.8%. The Pharmaceutical Contract Development and Manufacturing Market encompasses services provided by external partners to pharmaceutical companies, including drug development, manufacturing, and packaging. This market supports cost efficiency and scalability, allowing firms to focus on core competencies. Increasing demand for generic drugs, biologics, and personalized medicine drives growth, with technological advancements enhancing production capabilities and regulatory compliance.

The Pharmaceutical Contract Development and Manufacturing Market is experiencing robust growth, propelled by the increasing demand for outsourcing in drug development and manufacturing. The development segment, particularly in drug formulation and process development, is leading the market, driven by the need for specialized expertise and advanced technologies. Manufacturing services, especially in the production of biologics and biosimilars, follow closely, reflecting the growing focus on complex biologic drugs. Within these segments, the small molecule development sub-segment is a top performer, benefiting from the enduring demand for generic drugs. Meanwhile, the large molecule manufacturing sub-segment, encompassing monoclonal antibodies and recombinant proteins, is emerging as the second highest performer, fueled by advancements in biotechnology. The integration of digital technologies and automation in manufacturing processes is enhancing efficiency and quality control. Strategic partnerships and collaborations among pharmaceutical companies and contract service providers are further driving innovation and market expansion.

The Pharmaceutical Contract Development and Manufacturing Market is experiencing a dynamic shift in market share, pricing, and new product launches. Key players are leveraging innovative technologies to enhance their offerings, resulting in a competitive landscape that is both challenging and rewarding. The emphasis on cost-effective and efficient manufacturing processes has led to a surge in new product introductions. Companies are strategically adjusting pricing models to capture a larger market share, catering to the evolving demands of the pharmaceutical industry. This market is characterized by a strong demand for specialized services, driving growth and innovation. Competition benchmarking in this sector reveals a landscape dominated by a few key players, with smaller firms striving to carve out niches through specialized services. Regulatory influences play a pivotal role, with stringent compliance requirements shaping operational strategies. North America and Europe hold significant sway over regulatory standards, impacting global market dynamics. Emerging markets in Asia-Pacific are witnessing increased activity, driven by favorable policies and investment in infrastructure. The competitive environment is further intensified by mergers and acquisitions, which are reshaping market boundaries and fostering innovation. This comprehensive analysis underscores the importance of strategic agility and regulatory compliance in navigating the complex pharmaceutical landscape.

Geographical Overview:

The Pharmaceutical Contract Development and Manufacturing Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains a dominant player, driven by advanced healthcare infrastructure and substantial investments in pharmaceutical R&D. The region's strong regulatory framework and high demand for innovative therapies bolster market growth. In Europe, the market is flourishing due to increased outsourcing by pharmaceutical companies seeking cost efficiencies. The region's established pharmaceutical industry and emphasis on biotechnology further enhance its appeal. Asia Pacific is emerging as a lucrative growth pocket, propelled by rising healthcare expenditures and expanding generic drug production. Countries like India and China are becoming pivotal hubs for pharmaceutical manufacturing, attracting significant foreign investments. Latin America and the Middle East & Africa are also gaining traction. Latin America benefits from a growing focus on healthcare access and affordability, while the Middle East & Africa are recognizing the potential of contract manufacturing in addressing regional healthcare needs and fostering economic development.

Global tariff policies and geopolitical tensions are significantly influencing the Pharmaceutical Contract Development and Manufacturing Market, particularly in East Asia. Japan and South Korea are enhancing their domestic capabilities to mitigate dependency on foreign suppliers, driven by rising tariffs and supply chain vulnerabilities. China, under export restrictions, is accelerating its focus on self-reliance, investing heavily in local pharmaceutical R&D and manufacturing. Taiwan, while a key player in pharmaceutical production, is navigating geopolitical pressures with strategic alliances. The global parent market is experiencing robust growth, propelled by increasing demand for outsourced drug development. By 2035, the market is anticipated to thrive on innovation and strategic partnerships. Middle East conflicts contribute to fluctuating energy prices, indirectly impacting manufacturing costs and global supply chain stability.

Key Trends and Drivers:

The pharmaceutical contract development and manufacturing market is experiencing robust growth, driven by escalating demand for biologics and biosimilars. This trend is fueled by the increasing prevalence of chronic diseases and the need for innovative therapeutic solutions. Biopharmaceutical companies are outsourcing development and manufacturing processes to enhance efficiency and focus on core competencies. Another significant trend is the rise of personalized medicine, which necessitates specialized production capabilities. Contract manufacturers are investing in advanced technologies to accommodate small-batch, high-precision manufacturing. The growing emphasis on quality and regulatory compliance is also a critical driver, prompting companies to partner with experienced contract manufacturers to navigate complex regulatory landscapes. Furthermore, the globalization of pharmaceutical supply chains is creating opportunities for contract development and manufacturing organizations to expand their footprint in emerging markets. As pharmaceutical companies seek to reduce costs and enhance flexibility, strategic partnerships with contract manufacturers are becoming increasingly vital. These collaborations are enabling faster time-to-market for new drugs, thereby driving market growth.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Small Molecules
  • 4.1.2 Biologics
  • 4.1.3 Advanced Therapy Medicinal Products
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Active Pharmaceutical Ingredients (APIs)
  • 4.2.2 Finished Dosage Forms (FDFs)
  • 4.2.3 Intermediates
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Formulation Development
  • 4.3.2 Process Development
  • 4.3.3 Analytical Services
  • 4.3.4 Clinical Manufacturing
  • 4.3.5 Commercial Manufacturing
  • 4.3.6 Packaging
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Lyophilization
  • 4.4.2 Spray Drying
  • 4.4.3 Nanotechnology
  • 4.4.4 Continuous Manufacturing
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Cardiology
  • 4.5.3 Neurology
  • 4.5.4 Infectious Diseases
  • 4.5.5 Immunology
  • 4.5.6 Respiratory
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Solid
  • 4.6.2 Liquid
  • 4.6.3 Semi-Solid
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Pharmaceutical Companies
  • 4.7.2 Biotechnology Companies
  • 4.7.3 Research Institutes
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Batch Manufacturing
  • 4.8.2 Continuous Manufacturing
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Preclinical
  • 4.9.2 Clinical
  • 4.9.3 Commercial

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Form
    • 5.2.1.7 End User
    • 5.2.1.8 Process
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Form
    • 5.2.2.7 End User
    • 5.2.2.8 Process
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Form
    • 5.2.3.7 End User
    • 5.2.3.8 Process
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Form
    • 5.3.1.7 End User
    • 5.3.1.8 Process
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Form
    • 5.3.2.7 End User
    • 5.3.2.8 Process
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Form
    • 5.3.3.7 End User
    • 5.3.3.8 Process
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Form
    • 5.4.1.7 End User
    • 5.4.1.8 Process
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Form
    • 5.4.2.7 End User
    • 5.4.2.8 Process
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Form
    • 5.4.3.7 End User
    • 5.4.3.8 Process
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Form
    • 5.4.4.7 End User
    • 5.4.4.8 Process
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Form
    • 5.4.5.7 End User
    • 5.4.5.8 Process
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Form
    • 5.4.6.7 End User
    • 5.4.6.8 Process
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Form
    • 5.4.7.7 End User
    • 5.4.7.8 Process
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Form
    • 5.5.1.7 End User
    • 5.5.1.8 Process
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Form
    • 5.5.2.7 End User
    • 5.5.2.8 Process
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Form
    • 5.5.3.7 End User
    • 5.5.3.8 Process
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Form
    • 5.5.4.7 End User
    • 5.5.4.8 Process
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Form
    • 5.5.5.7 End User
    • 5.5.5.8 Process
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Form
    • 5.5.6.7 End User
    • 5.5.6.8 Process
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Form
    • 5.6.1.7 End User
    • 5.6.1.8 Process
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Form
    • 5.6.2.7 End User
    • 5.6.2.8 Process
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Form
    • 5.6.3.7 End User
    • 5.6.3.8 Process
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Form
    • 5.6.4.7 End User
    • 5.6.4.8 Process
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Form
    • 5.6.5.7 End User
    • 5.6.5.8 Process
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Catalent
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Lonza
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Recipharm
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Patheon
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Wu Xi App Tec
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Siegfried Holding
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Piramal Pharma Solutions
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Fujifilm Diosynth Biotechnologies
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Cambrex Corporation
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Almac Group
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Vetter Pharma
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Boehringer Ingelheim Bio Xcellence
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Ajinomoto Bio- Pharma Services
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Samsung Biologics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Thermo Fisher Scientific
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Corden Pharma
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Fareva
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Hovione
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 AMRI
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Baxter Bio Pharma Solutions
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us